"Under the agreement, Addex will regain rights to intellectual property and know-how and can pursue the program independently. www.addexpharma.com discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs."